Johnson, Matthew
▶ Watch on YouTubeCore ideas
Johnson opens with a taxonomy of psychedelics: "classic" psychedelics (psilocybin, LSD, DMT, mescaline) act as serotonin-2A receptor agonists and are, he stresses, physiologically "freakishly safe" — no known lethal overdose at the receptor level, and not addictive (their difficulty is convincing people to use them repeatedly, not to stop) — versus non-classic psychedelics like MDMA (pharmacologically a serotonin-releasing "presynaptic" drug, addictive on a milder end of the spectrum than cocaine, and more of a "heart trip" that leaves reality-perception relatively intact) and DMT/5-MeO-DMT at very high doses, which he describes as capable of producing a complete break from perceived reality while still leaving the experience memorable and narratable, unlike anesthetics. He discusses the well-documented phenomenon of people encountering seemingly autonomous "entities" on high-dose DMT, framing this cautiously through a naturalistic lens — the associative/learning machinery of the brain reaching for metaphor (archetypes, elves, aliens) when confronted with a magnitude of experience it has no other way to represent — while being candid that he can't rule out more exotic explanations and that, as a "radical empiricist," he tries to stay open to testing even claims that sound supernatural, since what counts as "natural" has historically expanded over time.
A large portion of the conversation covers his clinical research: a 15-person pilot study using psilocybin (combined with standard cognitive-behavioral smoking-cessation therapy) achieved an 80% biologically-confirmed smoking-abstinence rate at six months (60% at 2.5 years average follow-up) — far above the ~50% ceiling of the best existing multi-drug, year-long therapy regimens — and a subsequent randomized controlled trial against the nicotine patch was showing a 59% one-year abstinence rate for psilocybin versus 27% for the patch at the time of recording. He details the therapeutic protocol (extensive non-drug preparatory sessions, a single high "heroic" 30mg/70kg dose taken lying down with eye shades and music, guides present mainly as an anxiety "safety net" under the mantra "trust, let go, be open") and situates the work within his broader research on addiction via behavioral economics — explaining addiction through delay-discounting (the disproportionate devaluation of delayed rewards, which he links to real-world failures like inconsistent condom use) and demand-curve/price-elasticity analysis (arguing, for instance, that heavily taxing cigarettes to deter teens can simultaneously punish already-addicted poor smokers by taxing their addiction rather than their choice). He also describes original studies using controlled cocaine, methamphetamine, and alcohol administration to study drug effects on sexual risk-taking, finding stimulants directly increase the subjective rewarding value of sex (driving risk), while alcohol works more through disinhibition/reduced sensitivity to delayed consequences.
The conversation ranges widely into speculative territory: Johnson argues for treating tobacco/nicotine regulation pragmatically (nicotine itself isn't the primary harm — combustion byproducts are — so vaping could be a harm-reduction bridge if not over-regulated into a black market), for a public-health rather than purely criminal approach to drug policy generally (safe injection sites, contingency-management reward programs), and extensively into philosophy of mind: he distinguishes the "hard problem" of phenomenal consciousness (which he says psychedelics haven't actually illuminated, contrary to popular claims about the "default mode network" and ego dissolution, a story he says has been overstated and is now being challenged) from more tractable questions about the neural correlates of the sense of self, while personally speculating — with repeated caveats that this is outside his scientific expertise — that he leans toward panpsychism over pure computational-emergence as more parsimonious for explaining subjective experience. The episode closes on mortality: Johnson says he is afraid of the process of dying but not of nonexistence itself, describes how his research with terminal cancer patients using psilocybin has shaped his own acceptance of impermanence, and locates meaning in humanity's capacity for beauty, connection, and truth-seeking despite originating from, in his words, "filth."
Excerpts
On the puzzle of psychedelics' physiological safety despite their psychological intensity:
“Someone could take a thousand times what the effective dose is and it's not going to cause any organ damage, affect the brain stem, make them stop breathing... it's incredible that you can go on a hell of a journey in the mind, probably transformative, potentially in a deeply transformative way, and yet there's no dose that in most people would have a lethal effect.”
On why PCR-style overcorrection of "case" numbers matters for how he thinks about self-report and truth in psychedelic research (delayed discounting and addiction):
“It's this competition between what's good for me now and what's good for me later... someone telling themselves for years, 'I want to quit,' but then other times that same person is saying, functionally, 'I don't want to quit,' because they're saying, yeah, give me some. So in the moment it's very difficult to quit, and this isn't just something with huge clinical ramifications with addiction — it's like all humans do it. Anyone who's hit the snooze alarm in the morning...”
On his own reckoning with mortality, drawn from years of guiding psilocybin sessions with cancer patients:
“I think the meaning of life is to find meaning... it's the fact that we come from filth — we're animals, we're all descendant from murderers and rapists — and despite that background we are capable of this: the self-sacrifice, the connection, figuring things out, true science, other forms of truth-seeking, the beauty of music and art. The fact that that's possible is the meaning of life.”